Compare ADMA Biologics Inc (ADMA) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Manulife Financial Corporation — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Manulife Financial Corporation trades at $41 (market cap $68.99B). The key difference: Manulife Financial Corporation is far larger — about 32.4× ADMA Biologics Inc's market cap, and Manulife Financial Corporation pays a 3.22% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MFC | |
|---|---|---|
Market Cap | $2.13B | $68.99B |
Sector | Health | Financials |
52-Week High | $20.38 | $41.40 |
52-Week Low | $7.60 | $29.90 |
Enterprise Value | $2.20B | $65.55B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Manulife Financial (MFC) trades at $41.40, up 0.53% today, with a bullish technical signal from moving averages and strong analyst support (57% buy ratings). Recent Q1 2026 earnings missed expectations, but revenue grew to $53.01B in 2025, with net income of $5.78B. The company maintains a solid dividend, with a $0.49 payment scheduled for June 2026, and has demonstrated consistent operational cash flow growth, reaching $32.11B in 2025.
MFC's outlook is positive due to its AI initiatives and Asia growth, but risks include regulatory scrutiny and Q1 earnings miss. The stock's P/E of 16.92 and ROE of 13.14% suggest reasonable valuation, though investors should monitor debt levels and competitive pressures in insurance markets for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
